Iterum Therapeutics PLC
ITRM
查看详细走势图
0.302USD
+0.017+5.89%
收盘 02/06, 16:00（美东）报价延迟15分钟
14.80M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.89%
5天
-1.63%
1月
-13.76%
6月
-56.86%
今年开始到现在
-9.85%
1年
-79.73%
查看详细走势图
TradingKey Iterum Therapeutics PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Iterum Therapeutics PLC当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名150/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.50。中期看，股价处于下降通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Iterum Therapeutics PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Iterum Therapeutics PLC亮点
亮点风险
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
分析师目标
根据
2
位分析师
买入
评级
5.500
目标均价
+1828.47%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Iterum Therapeutics PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Iterum Therapeutics PLC简介
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
公司代码ITRM
公司Iterum Therapeutics PLC
CEOFishman (Corey N)
网址https://www.iterumtx.com/
相关品种
